Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Back

Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS

Professor, Faculty of Medicine & Dentistry
University of Alberta
University of Alberta; Department of Medicine; Division of Cardiology; Mazankowski Alberta Heart Institute

Dr. Glen Pearson is a Professor of Medicine in the Department of Medicine, Division of Cardiology at the University of Alberta. He is the Medical Co-Director of the Cardiac Transplant Clinic at the Mazankowski Alberta Heart Institute. He is the current Chair of Health Research Ethics Board (HREB; Biomedical Panel) for the University of Alberta. He teaches in the Cardio-Renal Block of the first Medical Practice course for medical and dental students. He also lectures in cardiovascular pharmacotherapeutics to the both the undergraduate and graduate health professions students at the University of Alberta (PharmD, MD, and MSc/PhD graduate programs). He also has an active interest in practice-based research. He has been a member of the Canadian Dyslipidemia Guideline primary panel since 2009 and was the Co-Chair for both the 2016 and 2021 CCS Dyslipidemia Guideline. He was a primary panel member of the 2018 CCS Position Statement on Familial Hypercholesterolemia (FH).
Dr. Pearson is an avid proponent of the role of advanced practice pharmacists in improving the delivery of collaborative health services and improving patient outcomes. He has been recognized for his contributions to achieving these goals thorough the receipt of numerous awards, including: the M.J. Houston Pharmacist of the Year Award from Alberta College of Pharmacists and the Alberta Pharmacists’ Association (2008), Alberta Pharmacy Centennial Award of Distinction (2011), APEX Partners in Practice Award for his Cardiac Transplant Team (2011), CSHP Pharmacotherapy Best Practices Award (2012/13), the distinguished Service Award from the Canadian Society of Hospital Pharmacists (2022), and a special recognition in 2008 for the achievement in becoming one of the first fifteen pharmacists in Canada to be granted additional prescribing authorization. He has also been conferred fellowship status in both the Canadian Society of Hospital Pharmacists (2003) and the Canadian Cardiovascular Society (2016).

Disclosure(s): Amgen: Consultant/Advisory Board (Terminated, May 31, 2024); GSK Pharmaceuticals: Consultant/Advisory Board (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Ultragenyx: Consultant/Advisory Board (Terminated, March 6, 2024)

Presentation(s):

Email Glen